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A comparison of endovascular revascularization
with traditional therapy for the treatment of acute
mesenteric ischemia
Zachary M. Arthurs, MD, Jessica Titus, MD, Mohsen Bannazadeh, MD, Matthew J. Eagleton, MD,
Sunita Srivastava, MD, Timur P. Sarac, MD, and Daniel G. Clair, MD, Cleveland, Ohio
Objectives: Few centers have adopted endovascular therapy for the treatment of acute mesenteric ischemia (AMI). We
sought to evaluate the effect of endovascular therapy on outcomes for the treatment of AMI.
Methods: A single-center, retrospective cohort review was performed on all consecutive patients with thrombotic or
embolic AMI presenting between 1999 and 2008. Patients with mesenteric venous thrombosis, nonocclusive mesenteric
ischemia, and ischemia associated with aortic dissection were excluded. Demographic factors, preoperative metabolic
status, and etiology were compared. Primary clinical outcomes included endovascular technical success, operative
complications, and in-hospital mortality.
Results: Seventy consecutive patients were identified with AMI (mean age, 64 13 years). Etiology of mesenteric ischemia
was 65% thrombotic and 35% embolic occlusions. Endovascular revascularization was the preferred treatment (81%) vs
operative therapy (19%). Successful endovascular treatment was achieved in 87%. Endovascular therapy required
laparotomy in 69% vs traditional therapy in 100% (P < .05), with a median 52-cm necrotic bowel resected (interquartile
range [IQR], 11-140 cm) vs 160 cm (IQR, 90-250 cm; P < .05), respectively. Acute renal failure and pulmonary failure
occurred less frequently with endovascular therapy (27% vs 50%; P < .05 and 27% vs 64%; P < .05). Successful
endovascular treatment resulted in amortality rate of 36% compared with 50% (P< .05) with traditional therapy, whereas
the mortality rate for endovascular failures was 50%. Endovascular therapy was associated with improved mortality in
thrombotic AMI (odds ratio, 0.10; 95% confidence interval, 0.10-0.76; P < .05).
Conclusions: Endovascular therapy has altered the management of AMI, and there are measurable advantages to this
approach. Using endovascular therapy as the primary modality for AMI reduces complications and improves outcomes.
(J Vasc Surg 2011;53:698-705.)
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vAcute mesenteric ischemia (AMI) accounts for only
0.1% of hospital admissions but is associated with a daunt-
ing mortality rate.1 The mainstay of treatment has relied on
prompt diagnosis and surgical treatment for the last 50
years; despite advances in treatment, morbidity and mortal-
ity for those presenting with AMI still remain high. Con-
temporary results report mortality ranges of 60% to 90%,2
and the mortality rate has remained fairly constant during
the past decade, with little improvement in results.3-5 Pre-
vention strategies have been aimed at aggressive anticoag-
ulation for patients with cardiac abnormalities, revascular-
izing patients with chronic mesenteric ischemia,6,7 and
even treating patients with asymptomatic high-grade three-
vessel disease.8
Endovascular therapy has several theoretic advantages
for the treatment of AMI. Avoiding urgent laparotomymay
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698imit the secondary injury after the initial ischemic insult. In
ddition, endovascular revascularization could potentially
estore bowel perfusion more rapidly than open visceral
xposure, surgical embolectomy, or surgical bypass graft-
ng. Initial endovascular revascularization may limit the
nitial ischemic insult and allow appropriate clinical resus-
itation before surgical exploration. Endovascular therapy
as been reported for the treatment of AMI in the form of
ase reports and case series; these initial results demonstrate
easibility, but the overall effect on outcomes is largely
nknown.9,10
The objective of this study was to review the manage-
ent of AMI at our institution, to evaluate the impact of
ndovascular therapy compared to traditional therapy, and
o determine the factors associated with mortality in the
reatment of acute mesenteric ischemia.
ETHODS
This study was an institutional review board-approved
tudy evaluating current therapy for AMI. A single-institu-
ional procedural database was queried for all consecutive
ases of AMI treated from December 1999 to December
008. Patients with thrombotic or embolic etiologies for
MI were included. Patients presenting with AMI second-
ry to the following conditions were excluded: mesenteric
enous thrombosis, nonocclusive mesenteric ischemia, aor-
ic dissections complicated by visceral ischemia, and visceral
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Volume 53, Number 3 Arthurs et al 699ischemia occurring as part of an investigational device ex-
emption protocol.
Preoperative risk factors, perioperative variables, and
outcomes were recorded from the electronic medical re-
cord. The determination of etiology (thrombotic or em-
bolic) was based on the operative dictation of treatment.
The classification of etiology was based on surgeon inter-
pretation of the clinical presentation, the radiographic find-
ings, and the operative findings; therefore, the etiology of
occlusion should be interpreted in this context.
Previous diagnoses were used to establish conditions
such as hypertension, diabetes, hyperlipidemia, smoking
history, chronic renal failure, peripheral arterial disease,
coronary artery disease, previous myocardial infarction,
atrial fibrillation, cardiac valvular disease, and history of
arterial or venous thrombotic event. Symptoms on presen-
tation, preoperative imaging, and laboratory values on ad-
mission were recorded. Computed tomography was re-
corded as positive if it confirmed an arterial occlusion.
Lactate level was recorded on presentation as well as the
maximum lactate during admission.
The treatment administered was categorized as “endo-
vascular” or “traditional” therapy. The endovascular algo-
rithm included attempts at endoluminal revascularization
with or without the need for laparotomy. Traditional ther-
apy included laparotomy with assessment of mesenteric
vasculature, surgical embolectomy, or bypass graft, and
bowel assessment for viability. The time from symptom
onset to treatment was based on the patient’s duration of
pain and included the diagnostic evaluation before revascu-
larization.
The number of vessels occluded, location of vessel
occlusion, complete vs partial occlusion, and intraoperative
adjuncts were based on the operating surgeon’s dictation.
Femoral and brachial access were both used for endovascu-
lar therapy; however, brachial access is now our preferred
approach.
Mechanical thrombectomy was used to achieve initial
reperfusion of the viscera, and then thrombolysis was initiated
based on residual arterial occlusions. Mechanical thrombec-
tomy was performed with the Angioject (MEDRAD Inter-
ventional/Possis,Warrendale, Pa), with orwithout adjunctive
tissue plasminogen activator (TPA); aspiration thrombectomy
was not uniformly recorded.
Thrombolysis was performed with a multi-sidehole in-
fusion catheter, with or without the addition of an infusion
wire; the catheter was positioned across the superior mes-
enteric artery origin beyond the first jejunal branches while
an infusion wire was positioned into the ileocolic artery.
The infusion wire extends the treatment area into the distal
ileocolic branches but also serves as an anchor for the
infusion catheter. Heparin was administered uniformly
through the arterial sheath. Vasodilator adjuncts, papaver-
ine and nitroglycerin, were also recorded.
After initiation of thrombolytic therapy, the decision to
continue thrombolysis was determined by the patient’s
overall condition and the initial response. Therapy was
continued 1 day in patients with residual arterial occlu- pions; in these cases, therapy was directed at occluded
essels by positioning the catheter or infusion wire into
pecific side branches (ileum, ileocolic, or right colic arter-
es).
The decision to perform a laparotomy was determined
y the patient’s clinical status and physical examination; but
ltimately, it was the decision of the operating staff vascular
urgeon and colorectal surgeon. The staff colorectal sur-
eon also made the decision of bowel viability and the
ength of bowel to resect.
Endovascular success was defined as return of bowel
erfusion without laparotomy, or return of bowel perfusion
ith laparotomy, without the need of open revasculariza-
ion by embolectomy or surgical bypass. Open revascular-
zation was categorized as embolectomy or bypass graft. A
ailed embolectomy that was followed by a bypass proce-
ure was recorded as a bypass graft.
Acute renal failure in the postoperative period was
efined as a creatinine1.5mg/dL in patients with normal
enal function or an increase of 20% in patients with
hronic renal failure. Pulmonary failure included patients
equiring intubation 72 hours. Myocardial infarction in-
luded electrocardiogram-confirmed ST depression and el-
vation in the setting of hemodynamic compromise. Gas-
rointestinal bleeding and access-site hemorrhage included
nly those events that required transfusion. The diagnosis
f stroke was based on clinical examination in conjunction
ith cerebral imaging. Mortality includes all in-hospital
eaths.
Patient variables were compared using univariate statis-
ics. Data are expressed as proportions for dichotomous
ariables and as mean  standard deviation or median and
nterquartile range (25th-75th percentiles) for continuous
ariables. Differences between two groups were deter-
ined by the t test for parametric data and the Mann-
hitney U test for nonparametric data. The 2 test was
sed for comparisons of nominal data, and the Fisher exact
est was used when appropriate. Odds ratios were used to
stimate the differences in likelihood of death determined
y operative, perioperative, and postoperative risk factors.
ultivariate analysis was not used secondary to the overall
ow number of observed cases within each group. Statistical
ignificance was set at P  .05. All analysis was performed
sing SPSS 15.0 software (SPSS Inc, Chicago, Ill).
ESULTS
During the 9-year study period, 70 patients with AMI
econdary to thrombotic or embolic arterial occlusions
ere treated. Presenting cohort characteristics and periop-
rative risk factors are listed in Table I and stratified by
reatment type. The mean age of the population was 64 
3 years. The etiology was thrombotic occlusion in 65%
ompared with embolic occlusion in 35%. Of the throm-
otic occlusions, 80% were native vessel thrombosis, 16%
ere stent occlusions, and 4% were iatrogenic occlusions.
ighty-five percent of emboli originated from a cardiac
ource, and the remaining 15% were the result of cardiac
rocedures. Baseline risk factors for atherosclerosis were
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March 2011700 Arthurs et alhigh. Risk factors for cardiac embolization were less fre-
quent, comprising previous myocardial infarction, 11%;
atrial fibrillation, 26%; and valvular heart disease, 12%. Only
13% of patients had had a previous venous or arterial
thrombotic event. Abdominal pain and nausea were the
most common presenting symptoms. Almost all patients
were evaluated with computed tomography.
Endovascular therapy was initiated in 56 patients
(81%), representing the preferred treatment modality for
acute mesenteric ischemia during this 9-year period. Only
minor differences were found when the groups treated with
endovascular therapy and traditional therapy were com-
pared. Patients treated with endovascular therapy were
slightly older (65  12 vs 60  13 years; P  .05). In
addition, the endovascular cohort was weighted with more
thrombotic occlusions (72%) compared with the traditional
cohort, which was weighted with more embolic occlusions
Table I. Univariate associations between preoperative and
All patie
Variable (n  7
Age, mean  SD, y 64 
Male, % 50
Etiology, %
Embolic 35
Thrombotic 65
Comorbidity, %
Hypertension 80
Diabetes mellitus 32
Hyperlipidemia 44
Active smoking 28
Chronic renal failure 12
Peripheral arterial disease 35
Coronary arterial disease 41
Previous myocardial infarction 11
Atrial fibrillation 26
Valvular disease 12
History of thrombotic event 13
Duration of symptoms onset to presentation,
median (IQR), h
36 (24-7
Abdominal pain, % 92
Nausea, % 68
Emesis, % 52
Bloody diarrhea, % 32
Preoperative imaging, %
Computed tomography, % 80
Positive, % 94
Duplex ultrasound imaging, % 9
Arteriogram, % 7
WBC count, mean  SD,  103/dL 16.5 
Blood urea nitrogen, median (IQR), mg/dL 17 (11-2
Creatinine, mean  SD, mg/dL 1.5 
Potassium, mean  SD, mg/dL 4 
pH, mean  SD 7.3 
Aspartate transaminase, median (IQR), U/L 25 (18-3
Alanine transaminase, median (IQR), U/L 20 (11-3
Lactate, median (IQR), mmol/L 2.4 (1.4-
Maxim lactate (IQR), mmol/L 3.9 (2.6-
IQR, Interquartile range; SD, standard deviation; WBC, white blood cell.
aDenotes comparisons between endovascular therapy and traditional therap
mean  SD. Nonparametric variables were analyzed by Mann-Whitney U
Proportions were analyzed by 2 test or Fisher exact test and expressed as p(64%). Although not statistically significant, those with praditional therapy tended to have a slightly higher lactate
oncentration on admission (median, 3.5 mmol/L) com-
ared with endovascular therapy (median, 2.3 mmol/L;
 .06). A comparison of the maximum lactate level
uring admission found no difference in values.
Descriptive variables for operative management are
isted in Table II. Duration of symptoms before treatment
as markedly longer in the patients treated with endovas-
ular therapy (median, 62 vs 26 hours; P  .05). Duration
f the initial endovascular procedure was similar to tradi-
ional therapy as where the distribution of vessels occluded
t presentation. The primary mode of endovascular therapy
as thrombolysis infusion, comprising 48% of the popula-
ion. TPA was used in all cases; the dose administered
aried depending on the provider (inmg/h: 1.0 in 63%, 0.5
n 19%, 0.25 in 12%, and 2.0 in 6% of patients). Vasodilator
herapy (papaverine or nitroglycerin) was used in 51% of
operative risk factors stratified by treatment type
Endovascular first Traditional
(n  56) (n  14) Pa
65  12 60  13 .05
54 42 .27
.05
28 64
72 36
77 93 .27
31 33 .99
43 47 .81
33 13 .20
16 0 .18
40 20 .16
43 33 .50
14 0 .34
26 26 .99
12 13 .99
11 20 .40
36 (24-96) 24 (10-48) .14
92 93 .99
69 67 .99
51 53 .88
31 34 .99
82 60 .10
95 100 .99
11 0 .33
7 7 .99
15.7  8 19.2  11 .27
18 (12-30) 12.5 (8-21) .10
1.6  4 1.1  1 .41
4  0.8 4  1 .89
7.4  0.1 7.1  1.1 .48
26 (18-33) 24 (19-157) .72
19 (14-32) 29 (9-143) .40
2.3 (1.4-3.5) 3.5 (2.6-4.9) .06
3.8 (2.4-6.0) 4.8 (2.6-6.1) .96
metric continuous variables were analyzed by the t test and are reported as
d are reported as median and interquartile (25th-75th percentiles) range.
ages.peri
nts
0)
13
2)
9
8)
3.2
0.8
0.4
5)
9)
3.8)
6.0)
y. Para
test anatients. All patients who received thrombolysis were
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Volume 53, Number 3 Arthurs et al 701treated with intra-arterial heparin administration through
the sheath. Duration of thrombolysis infusion was most
commonly 1 day (58%), with 36% of patients receiving 2
days, and 5% receiving 3 days of infusion. Mechanical
thrombectomy was done in 12% of patients in conjunction
with thrombolysis, and 33% required percutaneous translu-
minal angioplasty (PTA) and stent placement.
Eleven percent were treated with mechanical throm-
bectomy without thrombolysis, and of those patients, 22%
were treated with adjunctive PTA and stenting. Thirty-two
percent of patients were treated with primary PTA and
stenting. During the initial endovascular procedure, the
failure rate was 9%. Reasons for failure were attributed to
inability to cross the occlusion and obtain revascularization.
Of patients undergoing endovascular therapy, 31% avoided
laparotomy, and of those requiring bowel resection, a me-
dian of 52 cm of bowel was resected compared with 160 cm
for traditional therapy (P  .05). Median time from endo-
vascular revascularization until laparotomy was 4 hours.
Overall technical success for endovascular therapy was
87%; failures required embolectomy in 78% and revascular-
ization in 22%. Traditional therapy required revasculariza-
tion in 71% of patients. An evaluation of factors associated
with endovascular success found no differences in throm-
Table II. Comparison of operative management stratified
End
Variable
Symptoms onset to treatment, median (IQR), h
Procedure duration, median (IQR), min
Vessels occluded, %
SMA
Celiac artery  SMA
Location of occlusion 2-cm origin, %
Complete vessel occlusion, %
Endovascular treatment, %
Thrombolysis infusion
Mechanical thrombectomy
Adjunctive PTA/stent
Mechanical thrombectomy w/o thrombolysis
Adjunctive PTA/stent
Primary PTA/stent
Initial failures
Stents used, %
0
1
2
3-6
Laparotomy
Time to laparotomy, median (IQR), h
Ischemic bowel requiring resection, %
Bowel resection, median (IQR), cm
Endovascular technical success, %
Open revascularization, %
Embolectomy, %
Bypass, %
IQR, Interquartile range; PTA, percutaneous transluminal angioplasty; SD,
aDenotes comparisons between endovascular therapy and traditional therapy. Pa
Nonparametric variables were analyzed by Mann-Whitney U test and are rep
analyzed by 2 test or Fisher exact test and are expressed as percentages.botic (89%) vs embolic disease (85%; P  .94) or in wroximal occlusions (85%) vs distal occlusions (93%; P 
79). The technical success for partial occlusions was 100%
ompared with 82% for complete occlusions (P  .18).
uration of symptoms did not correlate with technical
uccess (median, 36; IQR, 16-130 hours) compared with
ailures (median, 48; IQR, 24-84 hours; P  .20).
Postoperative complications occurred more frequently
ith traditional therapy (Table III). Endovascular therapy
esulted in lower rates of acute renal failure and pulmonary
ailure. In addition, gastrointestinal bleeding was compara-
le between both treatment groups. Access site bleeding
equiring transfusion occurred in 9%. No patients sustained
hemorrhagic stroke; all cases were ischemic strokes. The
verall mortality was 39% for endovascular therapy vs 50%
or traditional therapy (P  .10). Patients who were suc-
essfully treated with endovascular therapy experienced a
ignificant reduction in mortality (36%) compared with
raditional therapy (50%; P  .05). Endovascular failures
esulted in a 50% mortality rate, similar to traditional
herapy.
Table IV lists univariate factors associated with death in
atients with AMI. At the time of presentation, increasing
ge, history of coronary artery disease, peripheral arterial
isease, and initial lactate 2.2 mmol/L were associated
ndovascular therapy and traditional therapy
ular therapy Traditional therapy
 56) (n  14) Pa
24-99) 26 (12-56) .05
81-172) 169 (38-250) .76
66 87 .62
34 13 .45
67 46 .68
74 . . . . . .
48 . . . . . .
12 . . . . . .
33 . . . . . .
11 . . . . . .
22 . . . . . .
32 . . . . . .
9 . . . . . .
47 . . . . . .
26 . . . . . .
21 . . . . . .
6 . . . . . .
69 100 .05
6-112) 26 (12-56) .05
84 94 .78
1-140) 160 (90-250) .05
87 . . . . . .
13 72 .05
71 90 .67
29 10 .19
ard deviation; SMA, superior mesenteric artery.
ric continuous variables were analyzed by t test and are reported asmean SD.
as median and interquartile range (25th-75th percentiles). Proportions wereby e
ovasc
(n
62 (
120 (
66 (2
52 (1
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ramet
ortedith increased risk of death. During the perioperative pe-
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ing resection also negatively affected overall mortality. In
the postoperative period, acute renal failure and pulmonary
failure were significantly associated with death.
Overall, endovascular therapy was not associated with a
survival benefit. Subgroup analysis demonstrated that there
Table III. Outcomes of acute mesenteric ischemia
stratified by treatment approach
Endovascular
first
Traditional
therapy
Variable (n  56) (n  14) Pa
Complications
Acute renal failure, % 27 50 .14
Pulmonary failure, % 27 64 .05
Myocardial infarction, % 2 0 .99
Gastrointestinal bleeding, % 7 14 .68
Access site bleeding, % 9 — —
Stroke, % 2 14 .12
Mortality, % 39 50 .15
Endovascular technical
success, %
36 — .05b
Endovascular failures, % 50 — .92b
aProportions analyzed by 2 test or Fisher exact test and expressed as
percentages.
bComparison of endovascular success and failures to the mortality of tradi-
tional therapy.
Table IV. Univariate associations with mortality among
patients presenting with acute mesenteric ischemia
Variable OR (95% CI) P
Age, per decade index 1.42 (1.0-1.99) .05
Etiology
Embolic (ref) 1.0
Thrombotic 0.79 (0.29-2.1) .64
Gender
Male (ref) 1.0 . . .
Female 0.69 (0.24-1.9) .48
Chronic renal failure 0.91 (0.20-1.9) .19
Peripheral arterial disease 2.9 (1.01-8.3) .05
Coronary artery disease 3.2 (1.1-8.0) .05
Previous myocardial infarction 1.2 (0.24-5.7) .99
Atrial fibrillation 1.5 (0.53-4.6) .43
History of thrombotic event 1.9 (0.46-7.7) .48
Duration of symptoms 24 hours 0.29 (0.08-1.0) .06
WBC 11  103/dL 1.0 (0.35-2.9) .97
Creatinine 1.5 mg/dL 1.4 (0.4-4.9) .60
Base deficit 2 4.4 (0.5-43) .70
Lactate 2.2 mmol/L 3.4 (1.0-11.3) .05
Maximum lactate 2.2 (1.4-3.3) .05
Type of therapy
Traditional (ref) 1.0 . . .
Endovascular first 0.55 (0.17-1.7) .23
Necrotic bowel 9.88 (1.11-97) .05
Acute renal failure 5.4 (1.6-18) .05
Acute pulmonary failure 12.4 (3.4-45) .05
Stroke 2.3 (0.13-39) .55
Access bleeding 0.73 (0.1-7.5) .79
Gastrointestinal bleeding 0.72 (0.1-7.5) .79
CI, Confidence interval; OR, odds ratio; WBC, white blood cell.was no significant difference in mortality for embolic occlu- iions for endovascular therapy (53%) vs traditional therapy
33%; P  .20); however, endovascular therapy signifi-
antly reduced the mortality for thrombotic occlusions
mortality, 33%; odds ratio, 0.10; 95% confidence interval,
.17-0.76; P  .05) compared with traditional therapy
mortality, 83%).
ISCUSSION
Endovascular therapy has the potential to dramatically
lter clinical outcomes in patients with AMI but given the
elative infrequency of this disease, it is difficult for any one
enter to obtain a large experience over a relatively short
nterval. The outcomes thus far are relegated to several
mall case series; to date, this study represents the largest
eries of patients with AMI treated with endovascular ther-
py. The 50% mortality of traditional therapy in our popu-
ation is comparable to the mortality rate of 52% to 70% in
ecent reports,1,5,11 providing a direct comparison with
atients treated with endovascular therapy during the same
eriod.
Previous case reports and small series that report mor-
ality rates of 0% to 17%10,12 for endovascular therapy are
argely subject to reporting bias. The current report offers a
omplete representation of all consecutive patients treated
ith AMI during the past 9 years at a largemultidisciplinary
eferral center, and the resultant mortality rate was 36% for
uccessful endovascular therapy compared with 50% for
ailures.
Although selection bias is evident in this retrospective
nalysis, there were few measurable differences in patients
reated with endovascular therapy compared with tradi-
ional therapy. The age difference, although statistically
ignificant, is clinically negligible. Disparities in etiologies
cross the two groups are partially attributable to progres-
ion in the treatment paradigm at our institution. Initially,
hrombotic arterial occlusions were first approached with
ndovascular therapy, followed by embolic occlusions as
xperience matured; therefore, a larger percentage of
hrombotic occlusions were treated with endovascular ther-
py. Thrombotic occlusions are typically associated with a
igher mortality (70%) compared with embolic occlusions
54%), presumably due to the large volume of bowel sub-
ected to ischemia.1 Despite these differences, the etiology
f occlusion did not affect the mortality rate in our popu-
ation. Taken into historical context, the endovascular
roup was weighted with thrombotic occlusions (72% of
atients) yet resulted in the lowest subgroup mortality
33%).
Our results contradict previous reports demonstrating
uration of abdominal pain portending a worse progno-
is.5,13 In the current series, patients undergoing endovas-
ular therapy presented with a median of 60 hours of
bdominal pain, and duration of symptoms24 hours was
nly weakly associated with death. Duration of abdominal
ymptoms also did not affect the likelihood of endovascular
uccess. These results can be explained by the variability in
bdominal pain in relationship to tolerance of intestinal
schemia, prior visceral atherosclerosis, degrees of collater-
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nal pain did not discriminate patients who would benefit
from endovascular therapy nor did it identify patients in
whom endovascular therapy was prohibitive.
Using endovascular therapy to treat AMI raises several
concerns that could potentially worsen patient outcomes.
This series provides a foundation to address some of those
concerns. First, endovascular therapy could potentially in-
crease the time for revascularization, subjecting the patient
to additional risk. In this series, patients treated with endo-
vascular therapy presented with a median of 62 hours of
symptoms, which was much longer than those undergoing
traditional therapy. Procedural time for endovascular revas-
cularization was essentially identical to traditional therapy.
It is important to note that partial bowel perfusion was
restored at the initial procedure, and thrombolysis was used
as an adjunctive agent to eliminate residual thrombus bur-
den.
Second, concerns that laparotomy is imperative for all
patients to address bowel viability was not proven in this
series: 31% of patients treated with endovascular therapy
avoided laparotomy altogether. Patients were monitored in
an intensive care unit, and exploration was reserved for
peritoneal findings on abdominal examination or clinical
deterioration, but exploration was not required in all pa-
tients.
In addition, endovascular failures could delay revascu-
larization and worsen outcomes. There was a 9% initial
endovascular failure rate in this series, with a total failure
rate of 13%, resulting in an 87% technical success rate for
endovascular therapy. Although patients successfully
treated with endovascular therapy experienced the lowest
mortality, endovascular failures approached the mortality
rate of traditional therapy (50% vs 50%). This subgroup
group did not experience any risk of death greater than
those who underwent traditional therapy. Although endo-
vascular failures did not increase the mortality rate, endo-
vascular successes reduced the mortality rate to 36% from
50%.
Endovascular therapy could negatively affect perioper-
ative and postoperative complications in this already mori-
bund population, but we actually found the contrary. En-
dovascular therapy afforded lower laparotomy rates, a
significantly smaller bowel resection at the time of surgical
exploration, and lower rates of renal and pulmonary failure.
All of these factors were associated with a lower mortality
rate in this group. The bleeding complications were rela-
tively low: These patients did not experience hemorrhagic
stroke, gastrointestinal bleeding was minor, and access-
related bleeding was 9%. No measurable deleterious effects
of endovascular therapy were identified within this cohort.
Endovascular failures were not associated with etiology
or location of occlusion, but complete occlusions appeared
to have a lower success rate than partial occlusions. Since
the time of this report, we have used hybrid treatment for a
few patients with AMI. After failed antegrade recanaliza-
tion of an occluded superior mesenteric artery, the oc-
cluded artery was recanalized retrograde from an abdomi- aal approach. The largest series available for open
etrograde stenting in the setting of AMI involved six
atients.12 The mortality rate was 17% in the hybrid
roup compared with 80% in the patients treated with
pen revascularization during the same period.12 This
echnique is another option to treat primary endovascu-
ar failures. Recanalization retrograde from the superior
esenteric artery does provide advantages after a failed
ntegrade approach. When this is used, it is often tech-
ically advantageous to then snare the wire from the
rachial access site and treat the primary lesion (angio-
lasty and stenting) from an antegrade approach.
This study also highlights a significant change in diag-
ostic evaluation. Although arteriography historically was
he primary diagnostic modality, computed tomography
ngiography was used in essentially all patients to secure the
iagnosis, and arteriography was primarily used with endo-
ascular treatment. Computed tomography angiography
ffords the surgeon the opportunity to use endovascular
herapy before laparotomy and also allows the clinician to
ssess the abdominal contents.14 Axial imaging of the oc-
lusion location, the origin of the visceral vessels, and access
essels is invaluable when approaching these patients.
Limitations of this study deserve mention. Surgeon
election bias cannot be avoided. Often, determining the
tiology of mesenteric occlusion can be challenging. The
lassification of etiology relied on surgeon interpretation of
he clinical presentation, radiographic findings, and opera-
ive findings, subjecting this variable to error. However, the
ariability and error associated with determining the exact
tiology is uniform across articles reporting outcomes for
MI.
Univariate comparisons of treatment groups were per-
ormed to identify confounding variables that may affect
utcome. Given the small number of patients, we did not
elieve that multivariate modeling would be appropriate.
A randomized trial for this disease process would be
hallenging, given the relatively infrequent occurrence and
cute presentation. In addition, these patients represent a
ohort that was appropriately diagnosed with AMI; pre-
umably, there are unidentified cases of AMI in which the
ascular surgery service did not evaluate the patient.
Despite these limitations, several strengths exist. This
epresents the largest single-center experience using endo-
ascular therapy for the treatment of AMI. In addition, this
eport affords details such as diagnostics, laboratory analy-
is, operative management, length of bowel resection, and
ostoperative complications that cannot be retrieved from
arge national databases.
ONCLUSIONS
Mesenteric ischemia remains one of the most lethal
iseases treated by vascular surgeons. Early recognition of
schemic symptoms and institution of surgical therapy have
imited potential for patient salvage. Endovascular therapy
as altered the management of AMI, and there are measur-
ble advantages to this approach. Using endovascular ther-
py as the primary modality for AMI reduces the need for
11
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March 2011704 Arthurs et allaparotomy, reduces length of bowel resection, and limits
acute renal and pulmonary failure. Most important, suc-
cessful endovascular therapy portends a survival advantage
in this moribund population.
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Dr Sean P. Roddy (Albany, NY ). I would like to congratu-
late Dr Arthurs and his colleagues at the Cleveland Clinic on an
excellent presentation and an excellent manuscript. They have
challenged the concept of immediate revascularization and man-
datory second-look laparotomy. I have four questions.
First, 81% of the patients who presented were treated with
endovascular therapy. Can you explain any reason—surgeon pref-
erence, physical exam, diagnostic angiographic findings, et ce-
tera—why the 19% were treated immediately with traditional sur-
gery?
Second, you employed thrombolytic therapy in half the pa-
tients and then continued an infusion for several days in 40% of this
subset. Did that subset have any difference in the need for laparot-
omy or the amount of bowel resected than the other groups? In
essence, did the time dedicated to the infusion therapy patients
result in an identifiable increase in morbidity?
Third, you were very aggressive with endovascular therapy in
this patient population but saw no overall decrease in mortality
compared with open surgery, as we might expect. Do you think
that this aggressive stance and time in the angiography suite, which
averaged 2 hours, raised the mortality overall in both treatment
arms? Do you think that converting to open surgery earlier may
have benefited both groups and not just the comparison between
the two?
Fourth and lastly, the majority of failures were in the embolus
patients. Do you believe that these patients are best treated with
open surgery, or are there subsets that you identified that can be
effectively managed with endovascular therapy?
Dr Zachary M. Arthurs. The first question is addressing the
selection bias. Eighty-one percent of the patients were chosen toifficult. The only aspect that really made the two groups disparate
as the etiology. The etiology, thrombotic vs embolic, was typi-
ally diagnosed in the operative suite or based on the computed
omography angiography. I thought that may have been a predis-
osing factor; however, it is not the case. Examining all measurable
ovariates, we couldn’t differentiate any specific reasons for bias
ther than surgeon preference. Is it a staff preference? I think
aybe early on it probably was; but today, it is departmental
reference.
The second aspect was if the patient underwent infusion
herapy and if infusion therapy extended 1 day or beyond, did it
ut them at a higher risk in regards to morbidity and mortality?
valuating the numbers, 56 patients underwent endovascular ther-
py altogether, 48%, or 28 patients, underwent lytic therapy. The
ajority of our patients received 1 day of therapy, and then there
re about seven patients that received 2 or more days of infusion
herapy. When we examined the mortality for those patients, there
s a trend for worse outcomes if they undergo infusion therapy
onger. These subgroups are really too small to draw any conclu-
ions; however, the mortality is 40% to 45%. And as well, did it
hange their laparotomy rate? Their laparotomy rate was around
8% to 72% in all of those subgroups.
The third question, if we converted to open sooner would it
ave changed the mortality in both groups? I think that avoiding
he insult of the laparotomy does give the opportunity to spare
ore bowel. Our median time to laparotomy was 4 hours; there-
ore, most of these patients are revascularized with endovascular
echniques at the time of their initial laparotomy. I don’t think that
mmediate laparotomy would have changed the mortality rate.
And number 4, when you do the subgroup analysis, the
mbolectomy patients appear to have a higher mortality. Again, I
hought that an open therapy would be more advantageous, but I
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if they have a higher mortality rate, but they are also the ones that
presented in the shortest amount of time and with the least amount
of collateralization. I think they are the highest-risk populations.
And so doing the subgroup, I can’t really say if one therapy is going
to be better than the other, but I think that endovascular therapy is
just as good as open therapy.
Dr Julie Ann Freischlag (Baltimore, Md). I think making the
diagnosis of mesenteric ischemia in the hospital is the toughest
diagnosis to make. Whenever we discuss it at morbidity and
mortality conference, it seems our interventions are always late. We
are frequently a day or two late in making the diagnosis, and
therefore, the patients do poorly. So in these patients, if you are
going to do endovascular therapy, which sounds like a great way to
go, how do you decide how long you are going to watch them? Doay lull yourself into feeling great that you revascularized them,
ut you may again wait too long to get them back to exploration.
DrArthurs. It is definitely a heterogeneous group. Currently,
e revascularize the patient and then decide on immediate or
elayed laparotomy. If they have peritonitis, the patient is explored
fter revascularization. If the patient has various degrees of abdom-
nal pain, then exploration is reserved for progression of symptoms.
ost of these patients remain extubated. If they are intubated and
ou can’t follow serial exams, that would be another reason to
onsider an early exploration. I agree with you. Some of these
atients come in very sick and it is clear. Some of them come in and
hey are not sick at all, and those are the patients that received 2 to
days of thrombolytic infusion; and then there are the ones in
etween that you just don’t know. I think if you put them in a
ritical care setting and you closely observe them, understandingthey all go to a laparotomy in 4 hours, or do you try to make a
clinical determination based on their exam? I have a feeling you
that you may have to explore them in the next 6 to 8 hours, it is a
reasonable approach.
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